A Phase I Study of MEK Inhibitor MEK162 Combined With Idarubicin and Cytarabine Induction in Patients With Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Cytarabine; Idarubicin
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.
- 25 Apr 2016 Status changed from suspended to active, no longer recruiting.